Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RIGL POWR Grades
- Quality is the dimension where RIGL ranks best; there it ranks ahead of 88.6% of US stocks.
- RIGL's strongest trending metric is Stability; it's been moving down over the last 179 days.
- RIGL ranks lowest in Stability; there it ranks in the 3rd percentile.
RIGL Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for RIGL is -24.07 -- better than only 0.8% of US stocks.
- Over the past twelve months, RIGL has reported earnings growth of 1,998.09%, putting it ahead of 99.31% of US stocks in our set.
- As for revenue growth, note that RIGL's revenue has grown -38.59% over the past 12 months; that beats the revenue growth of merely 4.6% of US companies in our set.
- Stocks that are quantitatively similar to RIGL, based on their financial statements, market capitalization, and price volatility, are THTX, XOS, RNWK, DNAY, and AVEO.
- Visit RIGL's SEC page to see the company's official filings. To visit the company's web site, go to www.rigel.com.
RIGL Valuation Summary
- RIGL's EV/EBIT ratio is -3.4; this is 131.48% lower than that of the median Healthcare stock.
- Over the past 243 months, RIGL's price/sales ratio has gone down 2.8.
Below are key valuation metrics over time for RIGL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RIGL | 2022-09-01 | 3.0 | -72.4 | -3.1 | -3.4 |
| RIGL | 2022-08-31 | 2.8 | -66.7 | -2.9 | -3.2 |
| RIGL | 2022-08-30 | 2.7 | -64.9 | -2.8 | -3.1 |
| RIGL | 2022-08-29 | 2.8 | -66.3 | -2.9 | -3.1 |
| RIGL | 2022-08-26 | 2.9 | -69.1 | -3.0 | -3.3 |
| RIGL | 2022-08-25 | 3.1 | -75.2 | -3.3 | -3.5 |
RIGL Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -638.74%.
- Its 5 year net income to common stockholders growth rate is now at 57.7%.
- Its 3 year net cashflow from operations growth rate is now at 100.54%.
The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 88.506 | -67.931 | -84.53 |
| 2022-03-31 | 84.953 | 0.196 | -84.859 |
| 2021-12-31 | 149.236 | 5.878 | -17.914 |
| 2021-09-30 | 147.277 | 9.392 | -14.51 |
| 2021-06-30 | 144.123 | 0.207 | -7.732 |
| 2021-03-31 | 133.878 | -69.047 | -11.487 |
RIGL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RIGL has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
- RIGL's asset turnover comes in at 0.825 -- ranking 30th of 682 Pharmaceutical Products stocks.
- GERN, NEOG, and VNDA are the stocks whose asset turnover ratios are most correlated with RIGL.
The table below shows RIGL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.825 | 0.994 | -0.082 |
| 2021-06-30 | 0.886 | 0.994 | -0.034 |
| 2021-03-31 | 0.912 | 0.992 | -0.069 |
| 2020-12-31 | 0.844 | 0.992 | -0.296 |
| 2020-09-30 | 0.765 | 0.993 | -0.259 |
| 2020-06-30 | 0.739 | 0.991 | -0.220 |
RIGL Price Target
For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.33 | Average Broker Recommendation | 1.33 (Strong Buy) |
RIGL Stock Price Chart Interactive Chart >
RIGL Price/Volume Stats
| Current price | $1.44 | 52-week high | $4.07 |
| Prev. close | $1.44 | 52-week low | $0.64 |
| Day low | $1.41 | Volume | 532,051 |
| Day high | $1.46 | Avg. volume | 3,683,172 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $2.16 | Market Cap | 248.87M |
Rigel Pharmaceuticals, Inc. (RIGL) Company Bio
Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.
Latest RIGL News From Around the Web
Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Kamada (KMDA) and Fate Therapeutics (FATE)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rigel (RIGL – Research Report), Kamada (KMDA – Research Report) and Fate Therapeutics (FATE – Research Report) with bullish sentiments. Rigel (RIGL) In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel, with a price target of $15.00. The company's shares closed last Wednesday at $1.59. According to TipRanks.com, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.1% and a 40.5% success rate. |
BMO Capital Keeps Their Buy Rating on Rigel (RIGL)BMO Capital analyst Gary Nachman reiterated a Buy rating on Rigel (RIGL – Research Report) today and set a price target of $4.00. The company's shares closed last Tuesday at $1.30. According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of -8.3% and a 39.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aquestive Therapeutics, and Ionis Pharmaceuticals. Rigel has an analyst consensus of Moderate Buy, with a price target consensus of $2.91, representing a 123.8% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7. |
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing PactRigel Pharmaceuticals Inc (NASDAQ: RIGL) and Forma Therapeutics Inc (NASDAQ: FMTX) entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. The FDA has accepted Forma's marketing application for olutasidenib with the Prescription Drug User Fee Act target date of February 15, 2023. Relat |
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue EstimatesRigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
Rigel Reports Second Quarter 2022 Financial Results and Provides Business UpdateRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. |
RIGL Price Returns
| 1-mo | 5.88% |
| 3-mo | 114.00% |
| 6-mo | -53.55% |
| 1-year | -64.00% |
| 3-year | -16.76% |
| 5-year | -43.08% |
| YTD | -45.66% |
| 2021 | -24.29% |
| 2020 | 63.55% |
| 2019 | -6.96% |
| 2018 | -40.72% |
| 2017 | 63.03% |
Continue Researching RIGL
Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...